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A drug being developed undergoes many stages of development to get to market. Information of the drugs 
absorption, distribution, excretion, metabolism, and systemic toxicology both short and long term are mandatory 
by regulatory agencies during clinical trials [1]. Drug-induced organ toxicity leads to 30% of all drugs failing to 
reach the market. Specifically, nephrotoxicity leads to 19% of all failures during phase III trials but only 2% 
during preclinical development stages. Current early stage tests for toxicity are widely perceived to be 
inadequate. 2D cell culture models can produce valuable data for drug discovery but do not accurately predict 
toxicity. A typical animal study to assess nephrotoxicity uses > 26 rodents, with substantially more animals if 
both sexes are required. An in vitro model that replaces or reduces animal use in toxicity testing is required for 
ethical reasons and to reduce species-specific effects. A drug can take 8-12 years and 0.8-1.2 billion US$ to get 
to market, hence there is a need for a more complex, human cell derived, in vitro model to accurately predict 
drug toxicity and reduce failure rates during the pre-clinical to clinical transition in drug development. 
 
Renal damage from toxicity can occur in a number of kidney compartments, but most toxic and drug induced 
injuries affect the proximal tubules either as a primary or secondary effect. Such damage can lead to systemic 
consequences [2]. The proximal tubule is a single layer of epithelial cells bound together by its extracellular 
matrix (ECM) that mediates the bloods composition through defined paracellular and transcellular pathways. 
The challenge is to develop a microfluidic tissue assay that models injury to the proximal tubule that is observed 
in nephrotoxicity. Ideally the assay should mimic the tubular structure of the kidney and reproduce the tubular 
response to known nephrotoxicants. 
 
Prior reports in the literature have proposed designs 
for microfluidic tissue assays similar to that illustrated 
in Fig. 1. Here a filtration structure that mimics the 
proximal tubule is placed on a membrane that 
separates two chambers in a trans-well cell culture 
configuration [3,4]. In all these cases proximal tubule 
epithelial cells are grown on a micro- or nanoporous 
polymer membrane within a microfluidic bioreactor. 
The need for a supporting substrate in these assays 
may reduce their biomimetic features of the cellular 
environment altering ECM construction, chemistry, 
complexity, and mechanical properties. 
 
Here we present a study of a proximal tubule model 
that uses cell sheets [13] without the need for a 
parallel supporting structure other than that 
generated by the cells’ ECM. We have utilized 
temperature responsive PIPAAm coated culture 
plates to harvest sheets of cells without digestive enzymes thus keeping the ECM intact. We then suspended 
this cell sheet (CS) over circle or rectangle holes in a Polydimethylsiloxane (PDMS) sheet. This process was 
developed in order to imbed a suspended cell sheet within a bioreactor. 
 
[1] Adeleye Y et al 2015, Toxicology. 332:102. 
[2]  S ́anchez-Romero, N. et al. 2016, Euro. J. Pharm., 790:36. 
[3]  Douville, N.J. et al. 2010, Analyt. Chem., 82:2505.  
[4]  Frohlich, E.M. et al. 2013, Lab Chip, 13:2311.  
[5] Yamato, M. and Okano, T. 2004. Materials Today, 7:42 
 
Fig. 1. (1) Schematic of membrane placement in 
bioreactor; (2) enlargement of the (A) cell sheet, 
seeder layer, and fibronectin (B) PDMS sheet (C) 
line showing gap between bioreactor halves (D) the 
bottom bioreactor; (3) test run of the PDMS sheet. 
